Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Mama Bear goes long! -- Ignore unavailable to you. Want to Upgrade?

To: JJMM who wrote (94)	8/25/1998 12:01:00 PM
From: Mama Bear	Respond to of 131

NLAB is OTC:BB. Barb

To: JJMM who wrote (94)	8/26/1998 1:42:00 AM
From: Marconi	Respond to of 131

Hello JJMM: NLAB -- my reaction is caution. It is out of Florida. Kazakstan is fairly remote to medical advances generally. The announcement had no scientific merit, and largely focused on a 'puff' future. 200 patients is enough size to obtain indications, although they do not state how many different cancer types were treated or methodology. For example, the patients would need to be randomly selected for both treatment and controls, with endpoints defined up front, not retrospectively. The endpoint of the study was not stated, whether in tumor reduction, elimination, reduced growth, etc. It cannot be ruled out that there may be merit, but lacking any scientific basis, this PR strikes me as a stump with a dash of mystique. Papers from refereed journals would be more solid, and in particular, any editorial replies are worth paying attention. Often that is where the meat is chewed regarding the merits of medical developments. Best regards, m